Included in the formulation
АТХ:L.01.X.C Monoclonal antibodies
Pharmacodynamics:It binds the receptors of vascular endothelium growth - VEGFR2, thereby stopping the angiogenesis of the tumor. As a result, the nutrition of the tumor is disrupted, the process of dividing cancer cells ceases.
Pharmacokinetics:After intravenous administration, the half-life period with monotherapy is 12-15 days. Subjected to tissue catabolism up to amino acids. It penetrates the placental and blood-brain barrier, it is found in breast milk.
Indications:It is used to treat stomach cancer, metastatic non-small cell or locally advanced lung cancer, metastatic colorectal cancer.
II.C15-C26.C19 Malignant neoplasm of rectosigmoidal joint
II.C15-C26.C16 Malignant neoplasm of stomach
II.C15-C26.C15.5 Malignant neoplasm of lower third of esophagus
II.C30-C39.C34.3 Malignant neoplasm of lower lobe, bronchus or lung
II.C30-C39.C34.2 Malignant neoplasm of middle lobe, bronchus or lung
II.C30-C39.C34.1 Malignant neoplasm of upper lobe, bronchus or lung
Contraindications:Invasion with a tumor of large blood vessels, tumor disintegration, age under 18, pregnancy and lactation, individual intolerance.
Carefully:Arterial hypertension, a history of thromboembolism, a history of gastrointestinal bleeding, severe hepatic insufficiency, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Intravenously slowly, for 60 minutes with a maximum rate of not more than 25 mg / min, 1 every 2 weeks for gastrointestinal cancer; 1 every 3 weeks with metastatic small cell lung cancer.
The highest daily dose: 10 mg / kg.
The highest single dose: 8 mg / kg.
Side effects:Central and peripheral nervous system: headache, dizziness, leukoencephalopathy, hallucinations, convulsions.
Respiratory system: nosebleeds.
Hemopoietic system: anemia, thrombocytopenia, and leukopenia.
The cardiovascular system: arterial hypertension, peripheral edema.
Digestive system: stomatitis, diarrhea, bleeding in the gastrointestinal tract.
Musculoskeletal system: convulsions.
Dermatological reactions: palmar-plantar erythrodysesthesia.
urinary system: proteinuria.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:With a planned surgical intervention, it is recommended to cancel the administration of the drug 4 weeks before the operation. In the postoperative period ramutsirumab Do not use until the wound is completely healed.
During the treatment period and three months after the last injection, people of reproductive age are recommended to use reliable methods of contraception.
When taking the drug is not recommended driving and working with moving machinery.